Source: OncLive, June 2025
Key Takeaways
- Cobolimab addition to dostarlimab improved major pathological response rates in high-risk resectable melanoma compared to monotherapy.
- The combination therapy was well-tolerated, with no treatment-related deaths and balanced toxicity profiles between arms.
- TIM-3 inhibition presents a promising strategy in melanoma treatment, warranting further investigation beyond PD-1 blockade.
- Safety profiles were comparable, with most adverse effects being grade 1 or 2, and no toxicities delaying surgery.